Literature DB >> 1571917

Total-body irradiation before bone marrow transplantation. Results of two randomized instantaneous dose rates in 157 patients.

M Ozsahin1, F Pène, E Touboul, B Gindrey-Vie, C Dominique, D Lefkopoulos, C Krzisch, J Balosso, L Vitu, L H Schwartz.   

Abstract

One hundred fifty-seven patients referred to the Department of Radiation Oncology of the Hôpital Tenon, Paris, France, between December 10, 1986 and December 31, 1989 for total-body irradiation (TBI) were treated according to the following two techniques: (1) either in one fraction (1000 cGy administered to the midplane at L4 and 800 cGy to the lungs) or (2) in six fractions (1200 cGy on 3 consecutive days to the midplane at L4 and 900 cGy to the lungs). The patients were randomized according to two instantaneous dose rates, called LOW and HIGH, in single-dose (6 versus 15 cGy/min) and hexafractionated (3 versus 6 cGy/min) TBI groups. There were 77 patients in the LOW group and 80 in the HIGH group, with 57 patients receiving single-dose TBI (28 LOW and 29 HIGH) and 100 patients receiving fractionated-dose TBI (49 LOW and 51 HIGH). In March 1991, the 4-year relapse-free and overall survival rates were 58.4% and 52.1%, respectively. The 4-year relapse-free survival and survival rates were 54.9% and 50.7% in the LOW group; 61.9% and 53.5% in the HIGH group (P = 0.69 and 0.82, respectively); 60.3% and 50.4% in the single-dose group; and 57.9% and 53.3% in the fractionated group (P = 0.65 and 0.78, respectively). There was no difference in the incidence of graft versus host disease, interstitial pneumonitis, or venoocclusive disease either between the LOW and the HIGH groups or between the single-dose and fractionated-dose TBI groups. The 4-year estimated cataract incidence was significantly higher in the single-dose HIGH instantaneous dose rate group than in the LOW instantaneous dose rate TBI group (P = 0.049). Multivariate analyses showed that instantaneous dose rate and fractionation do not influence the relapse-free and overall survival rates or the incidence of interstitial pneumonitis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1571917     DOI: 10.1002/1097-0142(19920601)69:11<2853::aid-cncr2820691135>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

1.  Current practice in total-body irradiation: results of a Canada-wide survey.

Authors:  R C N Studinski; D J Fraser; R S Samant; M S MacPherson
Journal:  Curr Oncol       Date:  2017-06-27       Impact factor: 3.677

Review 2.  Conditioning regimens for hematopoietic cell transplantation: one size does not fit all.

Authors:  Boglarka Gyurkocza; Brenda M Sandmaier
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

3.  Standardized flattening filter free volumetric modulated arc therapy plans based on anteroposterior width for total body irradiation.

Authors:  Rebecca Frederick; Alana Hudson; Alex Balogh; Jeffrey Q Cao; Greg Pierce
Journal:  J Appl Clin Med Phys       Date:  2020-02-11       Impact factor: 2.102

4.  Factors associated with pulmonary toxicity after myeloablative conditioning using fractionated total body irradiation.

Authors:  Hwa Kyung Byun; Hong In Yoon; Jaeho Cho; Hyun Ju Kim; Yoo Hong Min; Chuhl Joo Lyu; June-Won Cheong; Jin Seok Kim; Hyo Sun Kim; Soo-Jeong Kim; Andrew Jihoon Yang; Byung Min Lee; Won Hee Lee; Joongyo Lee; Ki Jung Ahn; Chang-Ok Suh
Journal:  Radiat Oncol J       Date:  2017-09-29

5.  Commissioning of a dedicated commercial Co-60 total body irradiation unit.

Authors:  Jay Burmeister; Adrian Nalichowski; Michael Snyder; Robert Halford; Geoff Baran; Brian Loughery; Ahmad Hammoud; Joe Rakowski; Todd Bossenberger
Journal:  J Appl Clin Med Phys       Date:  2018-03-11       Impact factor: 2.102

6.  Total-body irradiation before bone marrow transplantation for acute leukemia in first or second complete remission. Results and prognostic factors in 326 consecutive patients.

Authors:  Y Belkacémi; F Pène; E Touboul; B Rio; V Leblond; N C Gorin; A Laugier; C Gemici; M Housset; M Ozsahin
Journal:  Strahlenther Onkol       Date:  1998-02       Impact factor: 3.621

7.  Safety of total body irradiation using intensity-modulated radiation therapy by helical tomotherapy in allogeneic hematopoietic stem cell transplantation: a prospective pilot study.

Authors:  Tatsuya Konishi; Hiroaki Ogawa; Yuho Najima; Shinpei Hashimoto; Atsushi Wada; Hiroto Adachi; Ryosuke Konuma; Yuya Kishida; Akihito Nagata; Yuta Yamada; Satoshi Kaito; Junichi Mukae; Atsushi Marumo; Yuma Noguchi; Takashi Toya; Aiko Igarashi; Takeshi Kobayashi; Kazuteru Ohashi; Noriko Doki; Katsuyuki Karasawa
Journal:  J Radiat Res       Date:  2020-11-16       Impact factor: 2.724

8.  Automatic treatment planning for VMAT-based total body irradiation using Eclipse scripting.

Authors:  Jose R Teruel; Sameer Taneja; Paulina E Galavis; K Sunshine Osterman; Allison McCarthy; Martha Malin; Naamit K Gerber; Christine Hitchen; David L Barbee
Journal:  J Appl Clin Med Phys       Date:  2021-02-10       Impact factor: 2.102

9.  Total body irradiation and pneumonitis risk: a review of outcomes.

Authors:  S A Carruthers; M M Wallington
Journal:  Br J Cancer       Date:  2004-06-01       Impact factor: 7.640

10.  National survey of myeloablative total body irradiation prior to hematopoietic stem cell transplantation in Japan: survey of the Japanese Radiation Oncology Study Group (JROSG).

Authors:  Naoya Ishibashi; Toshinori Soejima; Hiroki Kawaguchi; Takeshi Akiba; Masatoshi Hasegawa; Kouichi Isobe; Hitoshi Ito; Michiko Imai; Yasuo Ejima; Masaharu Hata; Keisuke Sasai; Emiko Shimoda; Toshiya Maebayashi; Masahiko Oguchi; Tetsuo Akimoto
Journal:  J Radiat Res       Date:  2018-07-01       Impact factor: 2.724

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.